Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants John F. Sheridan - President, CEO & Director Leigh A.
The headline numbers for Tandem Diabetes Care (TNDM) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.47 per share a year ago.
Tandem Diabetes Care (TNDM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Tandem Diabetes Care (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The heavy selling pressure might have exhausted for Tandem Diabetes Care (TNDM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Tandem Diabetes' t:slim X2 pump with Control-IQ+ tech gains U.S. early access using FreeStyle Libre 3 Plus sensor.
Tandem Diabetes Care (TNDM) reported earnings 30 days ago. What's next for the stock?
Investors remain optimistic about TNDM, courtesy of its strong t:slim X2 performance and breakthrough innovations.
Tandem Diabetes' Q1 bottom line lags estimate. However, the company experiences strong sales growth both in and outside the United States.
Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Susan Morrison - EVP & Chief Administrative Officer John Sheridan - President & CEO Leigh Vosseller - EVP & CFO Conference Call Participants Matt Miksic - Barclays Mat Blackman - Stifel Steve Lichtman - Oppenheimer & Company Matthew O'Brien - Piper Sandler David Roman - Goldman Sachs Matthew Taylor - Jeffries Chris Pasquale - Nephron Research Anthony Petrone - Mizuho Financial Groups Joshua Jennings - TD Cowen Issie Kirby - Redburn Atlantic Nathan Trebek - Wells Fargo Mike Kratky - Leerink Partners Jayson Bedford - Raymond James & Associates William Plovanic - Canaccord Genuity Michael Polark - Wolfe Research Danielle Antalffy - UBS Stephanie Piazzolla - Bank of America Securities Shagun Singh - RBC Operator Good day, and thank you for standing by. Welcome to the Tandem Diabetes Care First Quarter 2025 Earnings Conference Call.
Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.